Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases
- 1 June 1998
- journal article
- Published by Elsevier in The Lancet
- Vol. 351 (9120) , 1905-1910
- https://doi.org/10.1016/s0140-6736(97)12445-x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Finally, a successful adjuvant therapy for high-risk melanoma.Journal of Clinical Oncology, 1996
- Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.Journal of Clinical Oncology, 1995
- The role of adjuvant therapy in melanoma managementCancer, 1995
- Results of adjuvant interferon study In WHO melanoma programmeThe Lancet, 1994
- The annual risk of melanoma progression. Implications for the concept of cureCancer, 1992
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958